We can change the story for childhood cancer patients.
Employing genomic data
and computational approaches can help identify targeted treatments that are less toxic and more effective.
Since childhood cancer tumor types are rare,
the only way to create large patient cohorts for analysis is through sharing data across institutions.
By enabling analysis
across different tumor types, we can identify tumors driven by the same molecular pathways. This could suggest repositioning an adult precision medicine drug for a pediatric cancer patient.
To facilitate data sharing
and to enable analysis of multiple tumor cohorts, we started the Treehouse Childhood Cancer Initiative.
Current long-term outcomes for childhood
cancer patients are unacceptable.
Although survival of childhood cancer patients has improved significantly in the last 30 years, this improvement has been due largely to the intensification of therapy and advances in supportive care.
Current standard-of-care regimens for high-risk childhood cancers consist of aggressive combinational chemotherapy, surgery, one or several bone marrow transplants, and radiation therapy. As a result, 4 out of 5 survivors of childhood cancers experience long-term effects from treatment. In 3 out of 5 cases these effects are disabling or result in life-threatening conditions such as infertility, heart disease, or secondary cancers.
These are the outcomes, based on a 30-year follow-up study, that kids face after treatments for childhood cancers.
This is a call to action.
Data from People Against Childhood Cancer
Dr. Robert Arceci was one of the leaders and visionaries behind the Treehouse Initiative. We will miss Bob greatly and are determined more than ever to make this initiative a success to get us closer to Bob’s dream of…